Abstract |
A bigenic MUC1.Tg/MIN mouse model was developed by crossing Apc/(MIN/+) (MIN) mice with human MUC1 transgenic mice to evaluate MUC1 antigen-specific immunotherapy of intestinal adenomas. The MUC1.Tg/MIN mice developed adenomas at a rate comparable to that of MIN mice and had similar levels of serum MUC1 antigen. A MUC1-based vaccine consisting of MHC class I-restricted MUC1 peptides, a MHC class II-restricted pan-helper peptide, unmethylated CpG oligodeoxynucleotide and GM-CSF caused flattening of adenomas and significantly reduced the number of large adenomas. Immunization was successful in generating a MUC1-directed immune response evidenced by increased MUC1 peptide-specific anti- tumor cytotoxicity and IFN-gamma secretion by lymphocytes.
|
Authors | Emmanuel T Akporiaye, Deborah Bradley-Dunlop, Sandra J Gendler, Pinku Mukherjee, Cathy S Madsen, Tobias Hahn, David G Besselsen, Sharon M Dial, Haiyan Cui, Katrina Trevor |
Journal | Vaccine
(Vaccine)
Vol. 25
Issue 39-40
Pg. 6965-74
(Sep 28 2007)
ISSN: 0264-410X [Print] Netherlands |
PMID | 17707958
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Adjuvants, Immunologic
- CPG-oligonucleotide
- Cancer Vaccines
- MUC1 tandem repeat peptide
- Mucin-1
- Oligodeoxyribonucleotides
- Peptide Fragments
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Adenoma
(immunology, pathology, therapy)
- Adjuvants, Immunologic
- Amino Acid Sequence
- Animals
- Cancer Vaccines
(administration & dosage, immunology)
- Disease Models, Animal
- Granulocyte-Macrophage Colony-Stimulating Factor
(administration & dosage, immunology)
- Humans
- Immunotherapy
- Intestinal Neoplasms
(immunology, pathology, therapy)
- Male
- Mice
- Mice, Transgenic
- Molecular Sequence Data
- Mucin-1
(administration & dosage, chemistry, genetics, immunology)
- Oligodeoxyribonucleotides
(administration & dosage, immunology)
- Peptide Fragments
(administration & dosage, chemistry, genetics, immunology)
- Vaccination
|